✦ LIBER ✦

A Phase I Trial of a 3-Day Topotecan Q 21 Days for Recurrent Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum

✍ Scribed by John V. Brown III; William A. Peters III; Mark A. Rettenmaier; Beth Y. Karlan; Robert A. Dillman; Michael R. Smith; Charles W. Drescher; John Paul Micha

Book ID: 112248311
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 40 KB
Volume: 79
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2000.6006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II, multicenter trial of weekly

A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum

✍ J.V. BROWN III; M.A. RETTENMAIER; K.L. LOPEZ; C. GRAHAM; J.P. MICHA; B. GOLDSTEI 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

A phase II trial of oxaliplatin, docetax

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

✍ Herzog, Thomas J.; Monk, Bradley J.; Rose, Peter G.; Braly, Patricia; Hines, Jef 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Treatment of recurrent or persistent pla

Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: A phase II trial of the Puget Sound Oncology Consortium

✍ Barbara A. Goff; Leona A. Holmberg; Dan Veljovich; Brenda F. Kurland 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 288 KB

Independent radiologic review of OCEANS,

Independent radiologic review of OCEANS, a phase III trial of carboplatin, gemcitabine, and bevacizumab or placebo for the treatment of platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

✍ C. Aghajanian; S. Makhija; T. Rutherford; S. Sharma; L. Nycum; M. Sovak; H. Nguy 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 136 KB

A phase I clinical trial of the mTOR inh

A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer

✍ M. Abu-Khalaf; A. Santin; E. Ratner; D. Silasi; K. ElSahwi; L. Baker; M. Luther; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Efficacy and safety of bevacizumab plus

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

✍ Halla S. Nimeiri; Amit M. Oza; Robert J. Morgan; Gregory Friberg; Kristen Kasza; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 256 KB